🔗 Share this article

Given that the United States continues making unprecedented adjustments to its immunization schedules, one figure appears in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by questioning COVID-19 vaccinations throughout the pandemic and has zeroed in on possible fatalities following Covid vaccination in her short position at the FDA.

Planned Overhauls to Childhood Vaccine Schedule

Public health authorities had intended to unveil major revisions to the pediatric vaccination calendar in December, aligning the US with the Danish vaccine program, sources say – a major change that would place the US out of step with much of the world with little proof for improved outcomes. The planned update has been postponed until the next year.

Rather than the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the gathering. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a tighter collaboration between the drug and biologics branches as Høeg and Prasad solidify control at the FDA – and it suggests a greater focus upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing some pediatric shot schedules in the US to become more similar to Denmark, a society with universal health coverage and a number of inhabitants about the population of Wisconsin’s.

So far public appearances, she has kept her attention on vaccines – usually the responsibility of Prasad, head of the FDA’s CBER – rather than drug regulation.

Concerns Over Qualifications

Dr. Høeg has no obvious experience in medication creation, regulation or management, which has been typical for previous leaders of the biologics center. She has served at the FDA as a senior adviser to the agency head and CBER since March.

“She doesn’t seem to have any of the qualifications” for running the CDER, said Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in managing a sizeable institution. She has no expertise in drug approvals.”

Past heads of the center would “grasp laws and regulations and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Objectively, she has not acquired the kind of background that previous people who headed CBER have had.”

This division has an enormous workload at the agency, the former commissioner stated.

“Everybody just pays attention on the innovative therapies, but the generic program authorizes a multitude of generic drugs. There is also a biologic copycat branch, OTC medication office and so forth, and all of those must be managed,” Dr. Woodcock said. “The thing you neglect, that is the part that I always told people is going to bite you.”

There is also, a substantial leadership aspect to the role, which supervises more than 5,000 staff members. “It is a massive management job, if you do it right,” she said.

Agency Reaction and Controversial Initiatives

When asked about inquiries about Dr. Høeg's qualifications and whether this selection represents increased cooperation among agency officials on immunizations, a spokesperson responded that the “concerns stem from incorrect premises”.

“This background matches the responsibilities of her job,” the representative explained, noting the time Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and vaccine surveillance”.

In her interim role, Høeg takes over the commissioner’s recently launched priority voucher program, a contentious one-day therapy clearance system that allegedly worried her preceding directors. “How are these medications being picked for this expedited pathway? Who is making the decisions?” Dr. Howard questioned. “There is a lot of secrecy going on at the agency right now.”

In general, he stated, “the agency looks to be trending towards less stringent rules of all drugs, except for vaccines.”

Documented Track Record on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if problematic, past, Howard said. She released a analysis using unverified volunteer-provided data to determine the incidence of heart inflammation following Covid vaccination. She advised the state of Florida top health official Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Part of her “policy goals” for the new federal leadership included revising rules for new vaccines and discontinuing “optional” immunizations, she remarked following the vote on a online show. At the FDA, Dr. Høeg has allegedly proposed preventing teenage boys from obtaining Covid vaccines.

“She’s an thorough true believer who starts off with her conclusions and reverse-engineers to retrofit the science in a highly disingenuous, dishonest manner,” Howard argued.

Taking Control and a “Push for Payback”

Høeg became part of fellow contrarians, {like|